Relating global bond yields to macroeconomic forecasts
JC Jankus - Journal of Portfolio Management, 1997 - search.proquest.com
Global portfolio managers are bombarded with research that attempts to forecast a broad
array of macroeconomic variables. A study tests the extend to which bond yields across …
array of macroeconomic variables. A study tests the extend to which bond yields across …
Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
…, J Baselga, R Kurzrock, MG Erlander, F Janku… - Cancer discovery, 2015 - AACR
… Janku reports receiving commercial research grants from Trovagene, Biocartis, and …
Janku is supported by a grant from the Sidney Kimmel Foundation. O. Abdel-Wahab is also …
Janku is supported by a grant from the Sidney Kimmel Foundation. O. Abdel-Wahab is also …
Central Bank Policy and Global Bond Yields
JC Jankus - Journal of Investing (Fall 1997), 2003 - papers.ssrn.com
Managers of global bond portfolios are accustomed to scrutinizing central bank policy because
changes in stance are believed to have predictable effects on bond portfolios. The author …
changes in stance are believed to have predictable effects on bond portfolios. The author …
[HTML][HTML] BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
F Janku, CRT Vibat, K Kosco, VR Holley, G Cabrilo… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF
V600E mutation (> 50% of patients). Patients with BRAF-mutant ECD can respond to BRAF …
V600E mutation (> 50% of patients). Patients with BRAF-mutant ECD can respond to BRAF …
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
Background Isocitrate dehydrogenase-1 (IDH1) is mutated in up to 25% of cholangiocarcinomas,
especially intrahepatic cholangiocarcinoma. Ivosidenib is an oral, targeted inhibitor of …
especially intrahepatic cholangiocarcinoma. Ivosidenib is an oral, targeted inhibitor of …
[HTML][HTML] Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma
…, VM Villalobos, GM Cote, H Burris, F Janku… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Surgery is the primary therapy for localized chondrosarcoma; for locally advanced
and/or metastatic disease, no known effective systemic therapy exists. Mutations in the …
and/or metastatic disease, no known effective systemic therapy exists. Mutations in the …
Initial results of Phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior …
…, J Wolf, R Ruiz-Soto, O Rosen, F Janku - Annals of …, 2018 - annalsofoncology.org
Background: DCC-2618, a kinase switch control inhibitor, broadly inhibits mutations in KIT
exons 9, 11, 13, 14, 17 and 18. Based on clinical activity observed in heavily pretreated GIST …
exons 9, 11, 13, 14, 17 and 18. Based on clinical activity observed in heavily pretreated GIST …
Diverse and targetable kinase alterations drive histiocytic neoplasms
… Janku reports receiving commercial research grants from Biocartis, Foundation Medicine,
and Trovagene and is a consultant/advisory board member for Trovagene. A. Dogan is a …
and Trovagene and is a consultant/advisory board member for Trovagene. A. Dogan is a …
Targeting the PI3K pathway in cancer: are we making headway?
F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated pathways in cancer
and, consequently, more than 40 compounds that target key components of this signalling …
and, consequently, more than 40 compounds that target key components of this signalling …
First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study
RJ Sullivan, JR Infante, F Janku, DJL Wong… - Cancer discovery, 2018 - AACR
… Janku reports receiving commercial research grants from BioMed Valley Discoveries,
Novartis, and Plexxikon, has ownership interest (including patents) in Trovagene, and is a …
Novartis, and Plexxikon, has ownership interest (including patents) in Trovagene, and is a …